SCHEDULE 13D/A: Significant Shareholder Updates Stake in OS Therapies Inc, Increasing Beneficial Ownership to 12.9%

Shalom Auerbach and Einodmil LLC have updated their beneficial ownership in OS Therapies Inc, reflecting an increase in shares held by Einodmil LLC through an additional transfer, while also disclosing a recent sale of shares.

Summary

• Shalom Auerbach and Einodmil LLC filed an Amendment No. 1 to their Schedule 13D regarding OS Therapies Inc.
• Shalom Auerbach beneficially owns 2,829,582 shares, representing approximately 12.9% of the Issuer's outstanding Common Stock.
• Einodmil LLC beneficially owns 2,806,211 shares, representing approximately 12.8% of the Issuer's outstanding Common Stock.
• The beneficial ownership percentages are based on 21,928,317 shares of Common Stock reported as outstanding as of January 28, 2025.
• On February 14, 2025, Einodmil LLC sold 100,000 shares of Common Stock for approximately $284,300.
• On February 27, 2025, Einodmil LLC received an additional 375,000 shares of Common Stock pursuant to a Transfer Agreement dated May 13, 2024.
• The Transfer Agreement initially allowed for an additional transfer of up to 600,000 shares, with the remaining 225,000 shares not received and returned to the counterparty.
• The Reporting Persons, as substantial owners, may control and influence the Issuer's corporate activities.
• No current plans for extraordinary corporate transactions, management changes, or changes to capitalization or dividend policy are stated, beyond potential future acquisitions or dispositions based on market conditions.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive. While there was a sale of shares, it was offset by a larger additional transfer, indicating a net increase in the reporting persons' overall beneficial ownership and continued interest as substantial owners. The lack of negative forward-looking statements also contributes to a neutral-to-slightly positive outlook from this specific filing.

Positives

• Einodmil LLC received an additional 375,000 shares of Common Stock, increasing their beneficial ownership.
• The reporting persons are substantial owners, potentially providing active oversight and stability to the company.

Negatives

• Einodmil LLC sold 100,000 shares of Common Stock for approximately $284,300, which represents a partial divestment.

Risks

• The Reporting Persons, as substantial owners, may be able to control the Issuer's business and influence corporate activities, which could potentially diverge from the interests of other shareholders.
• Future actions by the Reporting Persons, including acquisitions or dispositions of shares, will depend on various factors such as stock price levels, market conditions, the Issuer's financial condition, operations, prospects, and their liquidity needs, introducing uncertainty.

Future Outlook

The Reporting Persons, as substantial owners, may acquire additional shares or sell existing holdings in the future, depending on factors such as the Common Stock's price levels, general market and economic conditions, ongoing evaluation of the Issuer's business, financial condition, operations, prospects, and their liquidity needs. They do not currently have plans for extraordinary corporate transactions, management changes, or alterations to the Issuer's capitalization or dividend policy.

Industry Context

This filing is a routine update to a Schedule 13D, reflecting changes in a significant shareholder's beneficial ownership. It does not provide specific insights into broader industry trends or competitive landscape, but rather focuses on the ownership structure of OS Therapies Inc.

Related Party Transactions

• Einodmil LLC entered into a Transfer Agreement on May 13, 2024, with Paul Romness, which resulted in the initial transfer of 600,000 shares and a subsequent additional transfer of 375,000 shares of Common Stock.

Stakeholder Impact

• Shareholders: Changes in significant beneficial ownership can influence corporate control and future strategic decisions, potentially impacting share value and governance.

Next Steps

• The Reporting Persons may, from time to time, acquire additional shares of Common Stock.
• The Reporting Persons may, from time to time, retain and/or sell all or a portion of the shares of Common Stock held by them.
• The Reporting Persons may distribute shares of Common Stock to other entities.

Key Dates

Keywords

OS Therapies Inc, Schedule 13D/A, Beneficial Ownership, Shalom Auerbach, Einodmil LLC, Common Stock, Shareholding Update, SEC Filing, Institutional Investor, Ownership Stake